Shots:

• Alcon to acquire Aerie for $15.25/share representing a premium of 37% to Aerie’s last closing price with a total deal value of ~$770M. The transaction is expected to close in Q4’22
• The acquisition will advance the diversified portfolio with the addition of R&D capabilities to Alcon’s exisiting commercial expertise in the ophthalmic pharmaceutical eye drop space
• The acquisition will add Aerie’s Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, AR-15512 along with a pipeline of multiple clinical and preclinical ophthalmic pharmaceutical product candidates to Alcon’s portfolio

Ref: Businesswire | Image: Alcon